This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fawcett, P. T.
Right arrow Articles by Gibney, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fawcett, P. T.
Right arrow Articles by Gibney, K. M.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, January 2001, p. 79-84, Vol. 8, No. 1
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.1.79-84.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Effect of Immunization with Recombinant OspA on Serologic Tests for Lyme Borreliosis

Paul T. Fawcett,1,2,* Carlos D. Rose,2,3 Sandra M. Budd,1 and Kathleen M. Gibney1

Immunology Laboratory, Department of Research,1 and Division of Rheumatology, Department of Pediatrics,3 A. I. duPont Hospital for Children, Wilmington, Delaware, and Thomas Jefferson University, Philadelphia, Pennsylvania2

Received 26 July 2000/Returned for modification 20 September 2000/Accepted 19 October 2000

This study evaluated the effects of vaccination with OspA on the use of serologic tests as aids in the diagnosis of Lyme borreliosis. Sera from control and OspA-immunized mice and from OspA-immunized human volunteers were tested for serologic reactivity to Borrelia burgdorferi. Testing was performed with samples obtained prior to administration of vaccine and at 30 days following administration of an initial and a second dose of OspA vaccine. The assays used to assess serologic reactivity included an in-house-developed enzyme-linked immunosorbent assay (ELISA), an in-house-developed Western blot assay, two commercial Western blot tests, and a commercially available dot blot assay. Data obtained from this study demonstrate that immunization with the OspA vaccine will cause ELISA to yield positive results (as reported previously) for the majority of vaccine recipients. Results obtained from Western blot analysis indicate that vaccination with recombinant OspA induces production of antibodies which bind to several different borrelial proteins. The degree of reactivity detected by Western blotting varied greatly between the three assays used. The in-house assay showed the least reactivity, while one commercial Western blot test actually yielded positive test results for infection with B. burgdorferi. The usefulness of all three Western blot assays for the diagnosis of potential infection in a vaccine recipient is severely limited by the extensive reactivity caused by vaccination alone. Antibodies produced in response to OspA vaccination did not significantly affect the performance of the dot blot test; thus, it could provide a reliable means to test for infection with B. burgdorferi in OspA vaccine recipients.

* Corresponding author. Mailing address: Division of Immunology, A. I. duPont Hospital for Children, 1600 Rockland Rd., Wilmington, DE 19899. Phone: (302) 651-6776. Fax: (302) 651-6881. E-mail: pfawcett{at}nemours.org.

Clinical and Diagnostic Laboratory Immunology, January 2001, p. 79-84, Vol. 8, No. 1
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.1.79-84.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Mogilyansky, E., Loa, C. C., Adelson, M. E., Mordechai, E., Tilton, R. C. (2004). Comparison of Western Immunoblotting and the C6 Lyme Antibody Test for Laboratory Detection of Lyme Disease. CVI 11: 924-929 [Abstract] [Full Text]  
  • Fawcett, P. T., Rose, C. D., Maduskuie, V. (2004). Long-Term Effects of Immunization with Recombinant Lipoprotein Outer Surface Protein A on Serologic Test for Lyme Disease. CVI 11: 808-810 [Abstract] [Full Text]  
  • Hefty, P. S., Brooks, C. S., Jett, A. M., White, G. L., Wikel, S. K., Kennedy, R. C., Akins, D. R. (2002). OspE-Related, OspF-Related, and Elp Lipoproteins Are Immunogenic in Baboons Experimentally Infected with Borrelia burgdorferi and in Human Lyme Disease Patients. J. Clin. Microbiol. 40: 4256-4265 [Abstract] [Full Text]  
  • Fawcett, P. T., Rose, C. D., Gibney, K. M. (2002). In Vitro Assessment of Antiborrelial Activity of OspA Vaccine Sera. CVI 9: 919-920 [Abstract] [Full Text]  
  • Marques, A. R., Martin, D. S., Philipp, M. T. (2002). Evaluation of the C6 Peptide Enzyme-Linked Immunosorbent Assay for Individuals Vaccinated with the Recombinant OspA Vaccine. J. Clin. Microbiol. 40: 2591-2593 [Abstract] [Full Text]  
  • Gomes-Solecki, M. J. C., Wormser, G. P., Schriefer, M., Neuman, G., Hannafey, L., Glass, J. D., Dattwyler, R. J. (2002). Recombinant Assay for Serodiagnosis of Lyme Disease Regardless of OspA Vaccination Status. J. Clin. Microbiol. 40: 193-197 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»